企業プロフィール
Addex Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- ADXN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Switzerland and trades in the U
株価パフォーマンス
5.70 USD (-4.20%)
終値
最終更新: 2026年8月17日
8.1M USD
時価総額
株価変動の要因
Current closing-price context is not available for ADXN.
企業概要
Allosteric Modulator Developer
Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders. Its strategy combines internally controlled programs, partnered assets, and economic exposure to a broader pipeline advanced through the Neurosterix spinout.
Internally Controlled Programs
Lead candidate dipraglurant is an mGlu5 negative allosteric modulator with potential applications in recovery from brain injury, stroke, and traumatic brain injury. Addex also has a GABAB positive allosteric modulator program for chronic cough.
Partnered Development Model
Indivior is developing an Addex-originated GABAB PAM for substance use disorders. This partnership model allows Addex to retain program economics while external collaborators fund and operate selected development programs.
Neurosterix Exposure
Addex holds a 20% interest in Neurosterix, which is advancing M4 PAM and mGlu7 NAM programs for schizophrenia, psychosis, mood disorders, and other central nervous system conditions.
今後のカタリスト
- Phase 1 data for Neurosterix’s M4 PAM candidate NTX-253 are expected in summer 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。